Fundraising FoxVensana Capital — 2025 Investments
9 investments dated 2025 · listed companies and verified rows first · show all
Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
BiotechHealthtechMedical DevicesAustin, US
Adam Berman(Executive Officer, Director)inJacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)
BoardGeoff Pardo(Director)in
Board seatKirk NielsenMaria Berkman· per SEC Form D
Co-investorsBroadview VenturesRiverVest Venture PartnersTMC Venture FundCadence Healthcare VenturesGilde HealthcareGilmartin Capital LLC+2 more
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
AI & Machine LearningBiotechHealthtechMedical DevicesCarlsbad, US
Paul Flook(Executive Officer, Director)inGregory J. Gosch(Executive Officer, Director)Lynne Rollins(Executive Officer)Aditya Rajagopal(Director)inAxel Scherer(Director)
Board seatJustin Klein· per SEC Form D
Co-investorsAdjuvant CapitalGlobal BrainMoore Venture PartnersNew Enterprise Associates (NEA)Windham Capital PartnersDomain Associates+2 more
Overnight automated insulin delivery
Wilmington, US
John Sjolund(Chief Executive Officer of the Issuer)inJon Brilliant(Chief Financial Officer of the Issuer)
BoardPeter N. Townsend(Director)
Board seatJustin KleinAmrinder Singh· per SEC Form D
Co-investorsSerpentine Ventures
Okami Medical develops the LOBO vascular occlusion system, an occluder built on high-density, small-pore HDBRAID technology for fast arterial occlusion in the peripheral vasculature, along with SENDERO microcatheters and delivery catheters.
BiotechHardwareHealthtechMedical DevicesAliso Viejo, US
Brian J. Cox(Manager)inRhonda Robb(Executive Officer, Director)inRobert Rosenbluth(Director)
BoardDonald Milder(Director)Jonathan Root(Director)inPaul Lubock(Director)
Board seatMike KramerKirk Nielsen· per SEC Form D
Co-investorsUS Venture PartnersGilde Healthcare
Rampart develops radiation shielding solutions for interventional medical procedures, offering lead-free protective equipment including ceiling-mounted shields, mobile barriers, and monitoring systems for interventional radiology and cardiology labs.
HealthtechMedical DevicesBirmingham, US
Tom Livingston(Executive Officer, Director)inMichael Jackson(Executive Officer)Robert E. Foster, M.D.(Executive Officer, Director)
BoardChase Wise(Director)
Board seatMike KramerKirk Nielsen· per SEC Form D · $21.7M raise · filed May 2025
Luna Connect offers a cloud-based SaaS platform for financial institutions such as banks, credit unions, and insurers to digitise customer engagement, automate lending, onboarding, ID verification, and compliance workflows using no-code automation and AI-driven analytics.
AI & Machine LearningFintechSaaSGalway, IE
Brian D'Arcy(Founder)in
Co-investorsHaymaker VenturesWinklevoss Capital
Luna develops a small patch pump with automated insulin dosing for insulin pen users to help manage glucose levels overnight.
Digital HealthHealthtechMedical Devices
John Sjölund(Founder)inSean Saint(Founder)inJon Brilliant(Founder)
Co-investorsSerpentine VenturesWinklevoss CapitalInterlock Capital
Relief Cardiovascular develops transcatheter smart implant systems for volume management in congestive heart failure, including the Relief System, a preload-modulating implant for inferior vena cava flow modulation with autonomous hemodynamic monitoring.
BiotechHealthtechMedical DevicesCosta Mesa, US
Co-investorsAdvent Life SciencesBroadview VenturesGood Growth Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.